| Name | Title | Contact Details |
|---|
Progenika is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.
Molecular Templates is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers. Our Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies that possess unique biological properties.
Global Life Sciences Alliance (GLSA) is a dynamic and collaborative network of global CROs and clinical research vendors specializing in innovative solutions for Sponsors and CROs.The GLSA Team and Network accelerates clinical research timelines through innovation, leveraging extensive experience to foster collaboration and deliver superior outcomes. By mitigating the risks of vendor selection, GLSA ensures exceptional results for clinical trials.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 and 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.